Inactivating hepatitis C virus in donor lungs using light therapies during normothermic ex vivo lung perfusion

Marcos Galasso, Jordan J. Feld (), Yui Watanabe, Mauricio Pipkin, Cara Summers, Aadil Ali, Robert Qaqish, Manyin Chen, Rafaela V. P. Ribeiro, Khaled Ramadan, Layla Pires, Vanderlei S. Bagnato, Cristina Kurachi, Vera Cherepanov, Gray Moonen, Anajara Gazzalle, Thomas K. Waddell, Mingyao Liu, Shaf Keshavjee, Brian C. Wilson, Atul Humar and Marcelo Cypel ()
Additional contact information
Marcos Galasso: Toronto General Research Institute, University Health Network
Jordan J. Feld: University Health Network, Toronto General Hospital
Yui Watanabe: Toronto General Research Institute, University Health Network
Mauricio Pipkin: Toronto General Research Institute, University Health Network
Cara Summers: Toronto General Research Institute, University Health Network
Aadil Ali: Toronto General Research Institute, University Health Network
Robert Qaqish: Toronto General Research Institute, University Health Network
Manyin Chen: Toronto General Research Institute, University Health Network
Rafaela V. P. Ribeiro: Toronto General Research Institute, University Health Network
Khaled Ramadan: Toronto General Research Institute, University Health Network
Layla Pires: Toronto General Research Institute, University Health Network
Vanderlei S. Bagnato: São Carlos Institute of Physics, University of São Paulo Brazil
Cristina Kurachi: São Carlos Institute of Physics, University of São Paulo Brazil
Vera Cherepanov: University Health Network, Toronto General Hospital
Gray Moonen: Toronto General Research Institute, University Health Network
Anajara Gazzalle: Toronto General Research Institute, University Health Network
Thomas K. Waddell: Toronto General Research Institute, University Health Network
Mingyao Liu: Toronto General Research Institute, University Health Network
Shaf Keshavjee: Toronto General Research Institute, University Health Network
Brian C. Wilson: University of Toronto
Atul Humar: University Health Network
Marcelo Cypel: Toronto General Research Institute, University Health Network

Nature Communications, 2019, vol. 10, issue 1, 1-12

Abstract: Abstract Availability of organs is a limiting factor for lung transplantation, leading to substantial mortality rates on the wait list. Use of organs from donors with transmissible viral infections, such as hepatitis C virus (HCV), would increase organ donation, but these organs are generally not offered for transplantation due to a high risk of transmission. Here, we develop a method for treatment of HCV-infected human donor lungs that prevents HCV transmission. Physical viral clearance in combination with germicidal light-based therapies during normothermic ex-vivo Lung Perfusion (EVLP), a method for assessment and treatment of injured donor lungs, inactivates HCV virus in a short period of time. Such treatment is shown to be safe using a large animal EVLP-to-lung transplantation model. This strategy of treating viral infection in a donor organ during preservation could significantly increase the availability of organs for transplantation and encourages further clinical development.

Date: 2019
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-018-08261-z Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:10:y:2019:i:1:d:10.1038_s41467-018-08261-z

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-018-08261-z

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().